Atypical hyperplasias of the breast
https://doi.org/10.17650/1994-4098-2015-11-4-10-17
Abstract
The paper describes different types of atypical hyperplasia of the breast. It analyzes numerous works dealing with the evaluation of atypical ductal and lobular hyperplasias as a risk factor for breast cancer. The similar analysis has been also carried out in a cohort of women with a family history. The current capabilities of visual, cytological, morphological, and molecular biological diagnosis of atypical hyperplasias are considered. Modern-day guidelines for the treatment policy and monitoring of treated patients are given. The role and place of different chemoprevention options for this cohort of patients are considered. Whether preventive surgery may and should be performed particularly in a cohort of women with a family history is determined.
About the Authors
I. V. Vysotskaya
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia; 2 build. 4 Bolshaya Pirogovskaya St., Moscow, 119991, Russia
Russian Federation
Russian Federation
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia; 23 Kashirskoe Shosse, Moscow, 115478, Russia
Russian Federation
Russian Federation
References
1. Degnim A.C., Visscher D.W., Berman H.K. et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol 2007;25(19):2671–7.
2. Minami Y., Ohuchi N., Taeda Y. et al. Risk factors for benign breast disease according to histopathological type: comparisons with risk factors for breast cancer Jpn J Cancer Res 1998;89(2):116–23.
3. Dupont W.D., Page D.L. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146–51.
4. Hartman L.C., Degnim A.C., Santen R.J. et al. Special report: atypical hyperplasia of the breast – risk assessment and management options. N Engl J Med 2015;372(1):78–89.
5. http://www.cancer.gov/bcrisktool/.
6. Мнихович М.В. Внутрипротоковые пролиферативные поражения молочной железы: вопросы морфологической диагностики. Вестник РЗГМУ 2010:1–6. [Mnikhovich M.V. Intraductal proliferative lesions of mammary gland: issues of morphological diagnostics. Vestnik RZGMU = Herald of Ryazan State Medical University 2010:1–6.(In Russ.).
7. Goldstein N.S., Bassi D., Watts J.C. et al. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Am J Clin Pathol 2001;115(4):534–42.
8. Gudjonsson Т., Adriance M.C., Sternlicht M.D. et al. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005;10(3):261–72.
9. Dabbs D.J., Bhargava R., Chivukula M. Lobular versus ductal breast neoplasms: the diagnostic utility of pl20 catenin. Am J Surg Pathol 2007;31(3):427–37.
10. Lu Y.J., Osin P., Lakhani S.R. et. al. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998;58(20):4721–7.
11. Tjoe J.A., Neitzel G., Singh M. et al. Does expression of estrogen receptor, progesterone receptor, and HER2 in atypical breast lesions predict a subsequent clinically significant event? J Clin Oncol 2014;32(suppl 26): abstr 34.
12. www.medpanorama.ru.
13. Шабалова И.П., Джангирова Т.В., Волченко Н.Н., Пугачев К.К. Цитологический атлас: диагностика заболеваний молочной железы. М.; Тверь, 2005. [Shabalova I.P., Dzhangirova Т.V., Volchenko N.N., Pugachev K.K. Cytological handbook: diagnosis of mammary gland diseases. Мoscow; Tver, 2005. (In Russ.)].
14. Семиглазов В.Ф. Скрининг рака молочной железы. Практическая онкология 2010;11(2):60–5. [Semiglazov V.F. Screening of the mammary gland cancer. Prakticheskaya Onkologiya = Practical oncology 2010;11(2):60–5. (In Russ.)].
15. National Comprehensive Cancer Network. Clinical practice guidelines: breast cancer screening and diagnosis, version 1. 2014.
16. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection.
17. Cuzick J., Sestak I., Bonanni B. et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381(9880):1827–34.
18. Freedman A.N., Yu B., Gail M.H. et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol 2011;29(17):2327–33.
19. Gail M.H., Costantino J.P., Bryant J. et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91(21):1829–46.
20. Hoogerbrugge N., Bult P., Widt-Levert L.M. et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21(1):41–5.
Review
For citations:
Vysotskaya I.V., Letyagin V.P. Atypical hyperplasias of the breast. Tumors of female reproductive system. 2015;11(4):10-17. (In Russ.) https://doi.org/10.17650/1994-4098-2015-11-4-10-17
Views:
2684
Email this article 